Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
COVID-HIG · 1 trial · 1 indication
Number of participants with AEs and severity of AEs up to 72 hours post-dosing.
Number of participants and severity of AEs that led to discontinuation or temporary suspension of study treatment.
Number of participants with adverse events (AEs) and serious adverse events (SAEs) up to 56 days post-administration of a single dose of COVID-HIG.
Number of adverse events (AEs) and serious adverse events (SAEs) in all participants reporting AEs/SAEs up to 56 days post-dosing.
The area under the concentration-time curve from time 0 to the last quantifiable concentration of SARS-CoV-2 binding IgG antibodies after COVID-HIG dose. Data for PK calculations was collected: pre-dose, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 3, Day 4, Day 6, Day 8, Day 15, Day 29, Day 43, and Day 57.
Area under the concentration-time curve from time 0 to the last quantifiable concentration plus the additional area extrapolated to infinity of SARS-CoV-2 binding IgG antibodies after COVID-HIG dose. Data for PK calculations was collected: pre-dose, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 3, Day 4, Day 6, Day 8, Day 15, Day 29, Day 43, and Day 57.
The Cmax of SARS-CoV-2 binding IgG antibodies observed after COVID-HIG dose. Data for PK calculations was collected: pre-dose, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 3, Day 4, Day 6, Day 8, Day 15, Day 29, Day 43, and Day 57.
Time at which Cmax occurs (Tmax) after COVID-HIG dose. Data for PK calculations was collected: pre-dose, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 3, Day 4, Day 6, Day 8, Day 15, Day 29, Day 43, and Day 57.
The observed trough concentration of SARS-CoV-2 binding IgG antibodies 28 days after COVID-HIG dose. Data for PK calculations was collected: pre-dose, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 3, Day 4, Day 6, Day 8, Day 15, and Day 29.
| Arm | Type | Description |
|---|---|---|
| COVID-HIG Intramuscular | EXPERIMENTAL | Eligible subjects will be randomized to receive an 8.5mL dose of COVID-HIG by IM injections. COVID-HIG: COVID-HIG is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. |
| COVID-HIG Subcutaneous | EXPERIMENTAL | Eligible subjects will be randomized to receive an 8.5mL dose of COVID-HIG by SC injections. COVID-HIG: COVID-HIG is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. |
| COVID-HIG Intravenous | EXPERIMENTAL | Eligible subjects will be randomized to receive an 8.5mL dose of COVID-HIG by IV infusion. COVID-HIG: COVID-HIG is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. |
| Name | Type | Description |
|---|---|---|
| COVID-HIG | BIOLOGICAL | Anti-SARS-CoV-2 Immunoglobulin (Human) \[COVID-HIG\] is a purified liquid immunoglobulin G (IgG) preparation |
Inclusion Criteria: 1. Able and willing to provide written informed consent (voluntarily signed by the participant) prior to performing study procedures. 2. Females and males 18-59 years of age. 3. Have a body mass index (BMI) less than or equal to 35.0 kg/m\^2 4. Healthy, based on medical history ...
Top 20 of 28 competitors
COVID-HIG is an investigational monoclonal antibody being developed for SARS-CoV-2 infection, the illness caused by the virus that leads to COVID-19. It is intended for use in adults, and a Phase 1 clinical trial has been completed to evaluate its safety and pharmacokinetics.
COVID-HIG is being developed by Emergent BioSolutions Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol EBS. The company is conducting clinical research on this investigational monoclonal antibody for SARS-CoV-2 infection.
COVID-HIG is in Phase 1 of clinical development. A Phase 1 study has been completed, meaning the investigational monoclonal antibody is still in early-stage testing and has not yet been approved by regulatory authorities. It remains under investigation for safety and pharmacokinetics.
COVID-HIG has been studied in one completed Phase 1 clinical trial, registered as NCT05142306. This study evaluated the safety and pharmacokinetics of COVID-HIG administered through intramuscular, subcutaneous, or intravenous routes to SARS-CoV-2 uninfected adults in the United States.
COVID-HIG is a monoclonal antibody designed to target SARS-CoV-2, the virus that causes COVID-19. As an antibody, it is intended to bind to the virus and potentially neutralize it, though the specific molecular target has not been disclosed in available information.